UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40625 RELATIVITY ACQUISITION CORP. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporatio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Nevada 47-3975872 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1 ...

Financial Performance - Net sales for the three months ended March 31, 2025, were $12,135,000, a decrease of $1,926,000 or 13.7% compared to $14,061,000 for the same period in 2024[104] - Gross profit for the three months ended March 31, 2025, was $2,034,000, an increase of $128,000 or 6.72% from $1,906,000 in the same period of 2024, with a gross profit margin rising to 16.8% from 13.6%[108] - Operating expenses increased to $2,780,000 for the three months ended March 31, 2025, up $615,000 or 28.41% from $2,165,000 in the same period of 2024, representing 22.9% of net sales[109] - Net loss for the three months ended March 31, 2025, was $988,000, compared to a net loss of $706,000 for the same period in 2024, reflecting a 39.94% increase in losses[111] Cash Flow and Liquidity - Cash decreased by $468,000 or 62.15% to $285,000 as of March 31, 2025, compared to $753,000 as of December 31, 2024[105] - Working capital decreased by $1,400,000 or 11.89% to $10,376,000 as of March 31, 2025, from $11,776,000 as of December 31, 2024[105] - For the three months ended March 31, 2025, cash provided by operating activities was $1,525,000, compared to a cash flow use of $232,000 for the same period in 2024, indicating a significant improvement[122] - Cash used in investing activities was $1,217,000 for the three months ended March 31, 2025, up from $111,000 in the same period of 2024, reflecting ongoing investments in property and equipment[123] - Cash used in financing activities for the three months ended March 31, 2025, was $776,000, which included a decrease in borrowings under the Current Credit Facility by $284,000[125] - The company believes it has sufficient liquidity to meet its financial obligations for the next twelve months, based on current revenue visibility and backlog strength[119] Contracts and Backlog - Total unfilled contract values amounted to $270.3 million as of March 31, 2025, including a backlog of $120.6 million[103] Debt and Financing - The company entered into an Eighth Amendment on January 30, 2025, providing for an additional Term Loan of $1,640,000 for equipment acquisition[117] - As of March 31, 2025, the outstanding amount under the Revolving Line of Credit was $11,204,000, with $8,796,000 available for growth[119] - The company is exploring potential extensions or refinancing of its obligations under the Current Credit Facility, which may involve higher interest rates or more restrictive covenants[120] Customer Concentration - Lockheed Martin accounted for 39.6% of net sales in 2025, up from 25.9% in 2024, while RTX accounted for 28.9% in 2025, down from 33.4% in 2024[106] Operational Efficiency - The company plans to invest approximately $750,000 during the remainder of 2025 for new or upgraded equipment to enhance production efficiency[124] Accounting and Reporting - The company has not experienced any material changes to its critical accounting estimates compared to the previous year, maintaining consistency in financial reporting[129] - The increase in cash flow from operations was primarily due to a decrease in accounts receivable and the collection of contract costs receivable[122] Financial Ratios - The Fixed Charge Coverage Ratio achieved as of March 31, 2025, was 1.19x, exceeding the required 1.05x[113] Off-Balance Sheet Arrangements - The company has no off-balance sheet arrangements as of March 31, 2025, indicating a straightforward financial position[126]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36616 LogicMark, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or o ...

Revenue Performance - For the three months ended March 31, 2025, the company generated revenue of $289,037, a decrease of approximately 9.3% compared to $318,643 for the same period in 2024[234]. - Revenue from the company's network marketing business decreased by $10,532 or approximately 28.4%, while revenue from complementary health therapies decreased by $29,318 or approximately 10.4%[234]. Cost and Profitability - Cost of revenue increased by $17,528 or approximately 15.2%, amounting to $132,751 for the three months ended March 31, 2025[236]. - Gross profit for the three months ended March 31, 2025 was $156,286, representing a gross margin of 54.1%, down from 63.8% in the same period of 2024[239]. - Selling expenses increased by $12,704 or approximately 25.2%, totaling $63,052 for the three months ended March 31, 2025[241]. - Net loss increased by $9,825, resulting in a net loss of $712,919 for the three months ended March 31, 2025, compared to a net loss of $703,094 for the same period in 2024[247]. Cash Flow and Working Capital - As of March 31, 2025, the company had working capital of $23,775,576, significantly up from $1,656,571 as of December 31, 2024[248]. - Net cash used in operating activities for the three months ended March 31, 2025 was $1,453,874, compared to $1,243,460 for the same period in 2024[249]. - Net cash used in investing activities for the three months ended March 31, 2025 was $23,000,649, primarily from advances for investment[252]. - Net cash provided by financing activities for the three months ended March 31, 2025 was $22,994,658, compared to a net cash used of $899 in the same period of 2024[255]. Asset Management - As of March 31, 2025, the allowance for credit loss was recognized at $41,360, an increase from $32,857 as of December 31, 2024, reflecting a growth of approximately 25.3%[264]. - The carrying amounts of operating right-of-use assets were $189,059 as of March 31, 2025, down from $224,595 as of December 31, 2024, indicating a decrease of about 15.8%[261]. - The Company recorded inventory write-offs of $6,777 for the three months ended March 31, 2025, compared to $0 for the same period in 2024[259]. - The Company has not recognized any impairment losses on operating right-of-use assets and property, plant, and equipment as of March 31, 2025[261]. Revenue Recognition and Accounting Policies - The Company’s revenue recognition follows the five-step model under ASC Topic 606, ensuring that revenue reflects the transfer of goods and services to customers[268]. - The Company’s sales of skin care, health, and wellness products are recognized when control is transferred to the customer, with a return period of 60 days[271]. - The Company evaluates the need for an allowance for credit loss based on ongoing credit evaluations and current economic conditions[291]. - The Company has not hedged exposures denominated in foreign currencies, limiting direct foreign exchange risk[290]. - The adoption of ASU 2023-07 regarding segment reporting is expected to have no material impact on the consolidated financial statements[280]. Equity and Financing - The Company issued Representative's Warrants to purchase up to 115,500 shares at $4.4 per share, effective from October 13, 2023[266].

Revenue and Financial Performance - The Company recognized leasing revenue of approximately $2,991,000 for the three-month period ended March 31, 2025, compared to $4,253,000 for the same period in 2024, with PBRT services contributing approximately $1,642,000 and $2,649,000, respectively [97]. - Direct patient services revenues for the three-month period ended March 31, 2025, were approximately $3,121,000, a significant increase from $963,000 in the same period of 2024 [100]. - Revenues increased by $896,000 to $6,112,000 for Q1 2025 compared to $5,216,000 for Q1 2024 [107]. - Revenues from the leasing segment decreased by $1,262,000 to $2,991,000 due to lower Gamma Knife volumes and the expiration of two customer contracts [107]. - Direct patient services revenue increased by $2,158,000 to $3,121,000, primarily driven by the RI Companies following the acquisition on May 7, 2024 [107]. - Radiation therapy revenues from the acquired facilities and the Puebla facility totaled $2,374,000 for Q1 2025, compared to $0 for Q1 2024 [108]. - Total costs of revenue increased by $2,097,000 to $5,170,000 for Q1 2025 compared to $3,073,000 for Q1 2024 [113]. - Net loss attributable to American Shared Hospital Services increased by $744,000 to a loss of $625,000, or $0.10 per diluted share for Q1 2025 [123]. Assets and Liabilities - As of March 31, 2025, accounts receivable balances under ASC 606 were $6,120,000, compared to $1,882,000 as of March 31, 2024 [100]. - Working capital decreased by $4,821,000 to $11,032,000 as of March 31, 2025, compared to $15,853,000 at December 31, 2024 [125]. - The Company had cash, cash equivalents, and restricted cash of $11,491,000 as of March 31, 2025, an increase of $216,000 from December 31, 2024 [124]. - Long-term debt was $18,372,000 as of March 31, 2025, compared to $18,462,000 at December 31, 2024 [129]. - As of March 31, 2025, the Company had long-term debt of $19,926,000 on its condensed consolidated balance sheets [136]. Debt and Financing - The DFC Loan has a first tranche outstanding amount of $1,642,000 with a fixed interest rate of 3.67% and a second tranche of $1,806,000 at 7.49% [131]. - Interest expense increased by $84,000 to $433,000 for Q1 2025 due to increased borrowings [119]. - The Company is in compliance with all covenants related to the DFC Loan as amended and waived as of March 31, 2025 [133]. - The Company received a waiver and amendment from DFC for certain covenants as of December 31, 2023, and through December 31, 2024 [132]. Commitments and Obligations - Total commitments for purchasing and installing three Leksell Gamma Knife Esprit Systems and two Linear Accelerator systems amounted to $9,618,000 as of March 31, 2025 [138]. - The Company has commitments for service and maintenance of its Gamma Knife, LINAC, and PBRT equipment totaling $12,252,000 as of March 31, 2025 [140]. - The Company has an obligation to maintain a minimum fixed charge coverage ratio of 1.25 and a maximum funded debt to EBITDA ratio of 3.0 to 1.0 under the Credit Agreement [130]. Operational Developments - The Company acquired 60% of the equity interests of the RI Companies on May 7, 2024, which operate three radiation therapy facilities in Rhode Island [90]. - The Company operates ten domestic Gamma Knife units and one PBRT system in the United States as of March 31, 2025 [96]. - The Company’s facilities in Rhode Island, Peru, Ecuador, and Mexico are considered direct patient services, where contracts exist between the Company and individual patients [90]. - The approximate CMS reimbursement rates for PBRT treatments in 2025 are $578 for simple treatments and $1,276 for intermediate and complex treatments [92]. - The Company’s revenue recognition policies are based on ASC 842 and ASC 606, with revenues recognized when services are rendered and collectability is reasonably assured [96]. Related Party Transactions - The Company recorded total related party transactions of $1,558,000 for the three months ended March 31, 2025, compared to $2,586,000 for the same period in 2024 [142]. Equipment and Salvage Value - The Company has not assigned any salvage value to its PBRT or LINAC equipment as of March 31, 2025 [101].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTER ENDED March 31, 2025 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 000-08187 NEW CONCEPT ENERGY, INC. (State or Other Jurisdiction of Incorporation or Organization) Nevada 75-2399477 (I.R.S. Employer Identification No.) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _____________. OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION ...